Survivin expression in chronic myeloid leukemia.

[1]  S. Fukuda,et al.  The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34(+) cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells. , 2002, Blood.

[2]  G. Salvesen,et al.  IAP proteins: blocking the road to death's door , 2002, Nature reviews. Molecular cell biology.

[3]  D. Ginzinger.  Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. , 2002, Experimental hematology.

[4]  D. Altieri,et al.  The molecular basis and potential role of survivin in cancer diagnosis and therapy. , 2001, Trends in molecular medicine.

[5]  S. Fukuda,et al.  Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. , 2001, Blood.

[6]  M. Andreeff,et al.  Cytokine-regulated expression of survivin in myeloid leukemia. , 2001, Blood.

[7]  S. Moriyama,et al.  Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy , 2001, International journal of cancer.

[8]  D. Nicholson,et al.  From bench to clinic with apoptosis-based therapeutic agents , 2000, Nature.

[9]  E. G. Arias-Salgado,et al.  A novel (288delC) mutation in exon 2 of GPIIb associated with type I Glanzmann's thrombasthenia , 2000, British journal of haematology.

[10]  F. Sigaux,et al.  Expression and prognostic significance of survivin in de novo acute myeloid leukaemia , 2000, British journal of haematology.

[11]  J Diebold,et al.  Prognostic significance of survivin expression in diffuse large B-cell lymphomas. , 2000, Blood.

[12]  E. Macintyre,et al.  Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease , 1999, Leukemia.

[13]  R. Weiss,et al.  Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. , 1999, New England Journal of Medicine.

[14]  Z. Estrov,et al.  Chronic Myelogenous Leukemia: Biology and Therapy , 1999, Annals of Internal Medicine.

[15]  E. Felip,et al.  A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Jäättelä,et al.  Escaping cell death: survival proteins in cancer. , 1999, Experimental cell research.

[17]  D. Altieri,et al.  Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. , 1998, Cancer research.

[18]  D. Altieri,et al.  Anti-apoptosis gene, survivin, and prognosis of neuroblastoma , 1998, The Lancet.

[19]  C. Verfaillie.  Biology of chronic myelogenous leukemia. , 1998, Hematology/oncology clinics of North America.

[20]  D. Altieri,et al.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.

[21]  S. Korsmeyer,et al.  Molecular thanatopsis: a discourse on the BCL2 family and cell death. , 1996, Blood.

[22]  C. Thompson,et al.  Apoptosis in the pathogenesis and treatment of disease , 1995, Science.

[23]  B. Zehnbauer,et al.  Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. , 1994, Blood.

[24]  T. Ueda,et al.  Expression of the antiapoptotic gene survivin in chronic myeloid leukemia. , 2003, Anticancer research.

[25]  D. Altieri.  Validating survivin as a cancer therapeutic target , 2003, Nature Reviews Cancer.